Relapse of depression after ECT: a review

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Medicine

Background:

• Relapse of severe depression following successful electroconvulsive therapy (ECT) remains a significant clinical challenge.
• Approximately 50% of patients relapse without adequate follow-up treatment, with most relapses occurring within the first six months post-ECT.

Purpose of the Study:

• To review existing literature on relapse rates after electroconvulsive therapy (ECT).
• To identify factors, including biological markers and pre-ECT characteristics, that predict depressive relapse.
• To highlight areas for future research in predicting and preventing ECT relapse.

Main Methods:

• Systematic review of published literature on electroconvulsive therapy (ECT) and depressive relapse.
• Analysis of studies investigating biological markers (e.g., dexamethasone suppression test, cortisol hypersecretion, thyrotropin-releasing hormone stimulation test, REM sleep latency) as predictors.
• Examination of clinical factors such as medication resistance prior to ECT.

Main Results:

• Higher relapse rates are noted in specific subtypes like delusional depression and potentially "double depression."
• The dexamethasone suppression test, when persistently abnormal post-ECT, may indicate a higher risk of relapse.
• Pre-ECT medication resistance is a significant predictor of relapse, suggesting a need for intensified treatment strategies.

Conclusions:

• Predicting and preventing relapse after electroconvulsive therapy (ECT) requires further investigation.
• Biological markers and clinical history, such as medication resistance, offer potential insights into relapse risk.
• Ongoing research, including comparative trials of ECT with pharmacotherapy combinations, is crucial for improving long-term outcomes.